Quick Facts
| Property | Value |
|---|---|
| Category | Melanocortin Peptide |
| Risk Level | Moderate/High |
| Research Status | Strong Human Clinical Evidence |
| Administration | Subcutaneous Injection |
| Typical Frequency | Daily Loading / Maintenance 3× Weekly |
| Estimated Half-Life | Moderate Duration Peptide |
| Primary Research Interest | Tanning / Pigmentation / UV Response |
This material is provided strictly for educational and informational purposes related to peptide research and melanocortin compounds. Melanotan I (MT-1), also known as Afamelanotide, is a biologically active peptide capable of significantly altering melanocyte signaling, pigmentation pathways, and UV-response mechanisms. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Summary
Melanotan I (MT-1), later developed into the pharmaceutical product Afamelanotide, is a synthetic melanocortin peptide researched for its effects on melanin production, pigmentation enhancement, and UV-response pathways.
Unlike many peptides discussed within research communities, MT-1 possesses a substantial human evidence base, including clinical trials and regulatory approval of Afamelanotide for specific medical applications. Research demonstrates that melanocortin receptor stimulation can increase eumelanin production and improve tolerance to ultraviolet light exposure.
What People Commonly Claim
- Accelerated tanning
- Reduced UV exposure requirements
- Improved tanning consistency
- Reduced sunburn susceptibility
- Darker baseline pigmentation
- Fewer side effects than MT-2
What the Literature Actually Shows
- MT-1 demonstrably increases pigmentation through melanocortin receptor activation.
- Human clinical trials support increased tolerance to light exposure.
- The peptide promotes eumelanin production.
- Clinical efficacy has been demonstrated in humans.
- Long-term dermatologic monitoring remains important.
- Most clinical evidence comes from Afamelanotide implants rather than injectable research-peptide protocols.
CKF Transparency Note: MT-1 is unusual within the peptide world because many of its core biological claims are supported by human clinical evidence. However, most published studies utilized pharmaceutical Afamelanotide implants rather than the reconstituted injectable protocols commonly discussed within peptide communities.
2. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2 mL
- Final Concentration: 5.00 mg/mL
At this concentration:
• 250 mcg = 0.050 mL (5.0 units)
• 500 mcg = 0.100 mL (10.0 units)
• 1000 mcg = 0.200 mL (20.0 units)
3. Typical Research Protocols
- Product Strength: 5.00 mg/mL
- Loading Phase: 250 mcg daily for the first 2 weeks
- Maintenance Phase: 500–1000 mcg three times weekly
- Cycle Length: Seasonal cycles — commonly used during spring and summer, discontinued during fall and winter
- Special Notes: MT-1 still requires UV exposure in order to produce noticeable tanning effects, though significantly less exposure may be needed compared to unassisted tanning. Compared to MT-2, MT-1 is generally discussed as producing fewer gastrointestinal side effects and less appetite suppression, though tanning effects may develop more gradually.
CKF Evidence Note: The dosing schedules commonly discussed within peptide research communities differ substantially from the dosing methods used in the published Afamelanotide clinical literature. Approved human studies primarily utilized a 16 mg controlled-release implant administered approximately every 60 days rather than repeated subcutaneous injections. Consequently, commonly discussed injectable MT-1 protocols should be viewed as community-derived practices rather than dosing schedules established through controlled clinical trials.
4. Mechanism of Action
MT-1 functions primarily through activation of melanocortin receptors involved in melanocyte stimulation and melanin production.
- Melanocyte activation
- Eumelanin production enhancement
- Pigmentation signaling
- UV-response pathway modulation
- Photoprotective adaptation
- Melanocortin receptor activation
The compound is generally considered more selective than MT-2 and is less commonly associated with appetite suppression and sexual side effects.
5. Potential Benefits
- Potential enhancement of skin pigmentation
- Possible reduction in required UV exposure
- Improved tanning consistency
- Potential reduction in sunburn susceptibility
- More gradual pigmentation development compared to MT-2
- Potentially improved tolerability compared to MT-2
6. Potential Risks / Side Effects
Moderate/High
- Uneven pigmentation
- Darkening of freckles
- Darkening of existing moles
- Nausea
- Facial flushing
- Injection-site irritation
- Unknown long-term melanocyte signaling risks
Because MT-1 directly influences pigmentation pathways, users are commonly advised to monitor changes in freckles, moles, and other pigmented skin lesions over time.
7. Half-Life
MT-1 is commonly discussed as having a moderate-duration activity profile relative to other peptide compounds.
While circulating peptide levels decline over time, pigmentation effects typically accumulate gradually through repeated melanocyte stimulation and interaction with ultraviolet exposure.
Clinical Afamelanotide studies suggest that biological effects may persist considerably longer than circulating peptide concentrations alone would suggest.
8. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
9. Contraindications / Warnings
- History of melanoma
- Suspicious or changing skin lesions
- Severe dermatologic sensitivity disorders
- Pregnancy or breastfeeding
- Known hypersensitivity to melanocortin peptides
10. Further Study
Tier 1 — Essential Reading
- Afamelanotide for Erythropoietic Protoporphyria
- Advances in the Management of Erythropoietic Protoporphyria
- Afamelanotide in Protoporphyria and Other Skin Diseases
Tier 2 — Advanced Reading
- Afamelanotide for Treatment of the Protoporphyrias
- German Cohort Observational Study of Afamelanotide
- New Pharmacotherapies for the Erythropoietic Protoporphyrias
Additional Reading
- A Phase III Trial of Afamelanotide for Erythropoietic Protoporphyria
- Afamelanotide for Prevention of Phototoxicity in Erythropoietic Protoporphyria
Current Evidence Gaps
- Long-term dermatologic surveillance data
- Comparative studies of injectable MT-1 versus Afamelanotide implants
- Standardized injectable dosing protocols
- Long-term pigmentation outcomes in healthy individuals
- Direct evaluation of community-derived MT-1 protocols
11. Research References
- PubMed
- PubMed Central (PMC)
- Dermatology literature
- Photobiology research
- Melanocortin receptor research
- Pigmentation and UV-response journals
12. Last Reviewed
June 2026